R. James Neal's Insider Trades & SAST Disclosures
R. James Neal's most recent trade in Akari Therapeutics Plc - ADR was a trade of 225,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern R. James Neal.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akari Therapeutics Plc - ADR | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics Plc - ADR | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 4,464 | 4,464 | - | - | Series B Warrants (Right to Buy) | |
| Akari Therapeutics Plc - ADR | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 1.12 per share. | 06 Mar 2025 | 4,464 | 36,271 (0%) | 0% | 1.1 | 5,000 | American Depositary Shares representing Ordinary Shares |
| Akari Therapeutics Plc - ADR | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 4,464 | 4,464 | - | - | Series A Warrants (Right to Buy) | |
| Akari Therapeutics Plc - ADR | R. James Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 2,000,000 | 24,216,000 (1%) | 0% | 0.0 | 1,000 | Ordinary Shares, par value $0.0001 per share |
| Processa Pharmaceuticals Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 31,206 | 31,206 | - | - | Restricted Stock | |
| Palisade Bio Inc | R. Neal James | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 12,160 | 0 | - | - | Common Stock Options | |
| Palisade Bio Inc | Neal R. James | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 12,160 | 12,160 | - | - | Common Stock Options | |
| Palisade Bio Inc | R. James Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 6,880 | 0 | - | - | Common Stock Options | |
| Palisade Bio Inc | Neal James R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 6,880 | 6,880 | - | - | Common Stock Options | |
| Palisade Bio Inc | James Neal R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,820 | 10,920 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | R. Neal James | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,820 | 0 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Neal James R. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,100 | 5,100 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | R. James Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,100 | 0 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 101,365 | 101,365 | - | - | Restricted Stock | |
| Processa Pharmaceuticals Inc | James R. Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2023 | 14,407 | 0 | - | - | Restricted Stock | |
| Processa Pharmaceuticals Inc | James R. Neal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2023 | 14,407 | 14,407 | - | - | Common Stock | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2023 | 12,160 | 12,160 | - | - | Common Stock Options | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2023 | 5,100 | 5,100 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2022 | 17,797 | 17,797 | - | - | Restricted Stock | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 15 Jul 2022 | 25,000 | 36,822 (0%) | 0% | 4.0 | 100,750 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 25,000 | 218,056 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.55 per share. | 15 Jul 2022 | 20,883 | 15,939 (0%) | 0% | 29.6 | 617,095 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.19 per share. | 15 Jul 2022 | 3,212 | 12,727 (0%) | 0% | 31.2 | 100,175 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 15 Jul 2022 | 905 | 11,822 (0%) | 0% | 31.9 | 28,834 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 21 Mar 2022 | 50,000 | 61,822 (0%) | 0% | 4.0 | 201,500 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 21 Mar 2022 | 50,000 | 11,822 (0%) | 0% | 29.0 | 1,450,250 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 50,000 | 106,250 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 2,339 | 103,911 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 21 Mar 2022 | 2,339 | 14,161 (0%) | 0% | 4.0 | 9,426 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 21 Mar 2022 | 2,339 | 11,822 (0%) | 0% | 30.0 | 70,209 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.03 per share. | 21 Mar 2022 | 1,111 | 12,933 (0%) | 0% | 4.0 | 4,477 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 21 Mar 2022 | 1,111 | 11,822 (0%) | 0% | 30.0 | 33,348 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 1,111 | 102,800 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 60,000 | 60,000 | - | - | Non-Qualified Share Option (right to buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.36 per share. | 25 Jun 2021 | 7,170 | 13,678 (0%) | 0% | 33.4 | 239,202 | Common Shares |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 34.30 per share. | 25 Jun 2021 | 1,171 | 12,507 (0%) | 0% | 34.3 | 40,170 | Common Shares |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.13 per share. | 25 Jun 2021 | 686 | 11,821 (0%) | 0% | 35.1 | 24,101 | Common Shares |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 5,091 | 5,091 | - | - | Stock Option (Right to Buy) | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 4,406 | 4,406 | - | - | Stock Option (Right to Buy) | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 3,398 | 3,398 | - | - | Stock Option (Right to Buy) | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 1,359 | 1,359 | - | - | Stock Option (Right to Buy) | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 1,298 | 1,298 | - | - | Stock Option (Right to Buy) | |
| Palisade Bio Inc | James R. Neal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 849 | 849 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Grant, award, or other acquisition of securities at price $ 25.00 per share. | 09 Apr 2021 | 8,000 | 8,000 | - | 25 | 200,000 | Depositary Shares - 8.375% B Cumulative Stock |
| XOMA Corp | James R. Neal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 60,268 | 60,268 | - | - | Non-Qualified Share Option (right to buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.50 per share. | 15 Dec 2020 | 26,000 | 46,849 (0%) | 0% | 5.5 | 143,000 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 41.15 per share. | 15 Dec 2020 | 20,294 | 26,555 (0%) | 0% | 41.1 | 835,098 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Grant, award, or other acquisition of securities at price $ 25.00 per share. | 15 Dec 2020 | 8,000 | 8,000 | - | 25 | 200,000 | 8.625% Series A Cumulative Perpetual Preferred Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 42.04 per share. | 15 Dec 2020 | 5,706 | 20,849 (0%) | 0% | 42.0 | 239,900 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2020 | 13,126 | 26,000 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 32.96 per share. | 20 Nov 2020 | 13,126 | 20,849 (0%) | 0% | 33.0 | 432,662 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.50 per share. | 20 Nov 2020 | 13,126 | 33,975 (0%) | 0% | 5.5 | 72,193 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.50 per share. | 20 Nov 2020 | 6,874 | 27,723 (0%) | 0% | 5.5 | 37,807 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2020 | 6,874 | 39,126 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 32.46 per share. | 20 Nov 2020 | 6,448 | 21,275 (0%) | 0% | 32.5 | 209,315 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.35 per share. | 20 Nov 2020 | 426 | 20,849 (0%) | 0% | 33.4 | 14,208 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2020 | 10,000 | 46,000 | - | - | Stock Option (Right to Buy) | |
| XOMA Corp | James R. Neal | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.50 per share. | 05 Nov 2020 | 10,000 | 30,849 (0%) | 0% | 5.5 | 55,000 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 05 Nov 2020 | 9,273 | 21,576 (0%) | 0% | 25.9 | 240,212 | Common Stock |
| XOMA Corp | James R. Neal | Director, CEO | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 05 Nov 2020 | 727 | 20,849 (0%) | 0% | 27.5 | 19,993 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges